Transforming Growth Factor

AVID200 led to significant reduction in serum transforming growth factor beta levels and improved platelet counts among patients with advanced myelofibrosis, according to study results presented at ASH Annual Meeting and Exposition.

Transforming growth factor beta mutation biomarkers may help identify patients at high risk for cancer of the liver, pancreas and gastrointestinal system, according to data published in Gastroenterology.